Atenolol-Ratiopharm 25: description, use, contraindications and side effects
Atenolol-Ratiopharm 25 is a beta1-blocker, which is used as a medicine for the treatment of arterial hypertension, angina pectoris, acute myocardial infarction (with stable hemodynamic parameters), tachycardia (sinus, atrial, ventricular, paroxysmal, etc.), extrasystole, flutter and flicker. atria, hyperkinetic cardiac syndrome, mitral valve prolapse, neurocirculatory dystonia of the hypertensive type, complex therapy of hypertrophic cardiomyopathy, pheochromocytoma, thyrotoxicosis, essential tremor and migraine (prevention).
Atenolol-Ratiopharm 25 is manufactured by Ratiopharm GmbH in Germany. It contains the active substance atenolol, which is a cardioselective beta-blocker. This means that atenolol only blocks beta1 adrenergic receptors in the heart, resulting in a lower heart rate and decreased force of heart contractions.
Contraindications to the use of Atenolol-Ratiopharm 25 include hypersensitivity to atenolol, sinus bradycardia (heart rate less than 50 beats per minute), sinoatrial block, sick sinus syndrome, degree II-III atrioventricular block, arterial hypotension (systolic blood pressure less than 90 mm Hg. Art.), acute or chronic heart failure in the stage of decompensation, cardiogenic shock, impaired peripheral circulation and breastfeeding.
Patients taking Atenolol-Ratiopharm 25 may experience some side effects. These may include fatigue, weakness, dizziness, headache, drowsiness or insomnia, nightmares, depression, anxiety, confusion, short-term memory loss, hallucinations, decreased reactivity, paresthesia, seizures, blurred vision, decreased secretion of saliva and tear fluid. , conjunctivitis.
The following side effects from the cardiovascular system and blood may also occur: bradycardia, palpitations, impaired myocardial conduction, decreased blood pressure, development of heart failure, deterioration of peripheral circulation and the development of reversible arterial occlusion. Patients with asthma, bronchial obstruction, obstructive bronchitis, chronic obstructive pulmonary disease and other diseases of the respiratory system may experience asthma attacks and deterioration of respiratory function. Dry mouth, nausea, vomiting, diarrhea, constipation, increased liver enzymes, impaired kidney function, decreased blood glucose levels, increased triglycerides and cholesterol levels may also occur.
Before using Atenolol-Ratiopharm 25, you must consult with your doctor, who will determine the dosage and duration of treatment based on the individual characteristics of the patient and the nature of the disease. It is also worth considering that discontinuation of treatment with Atenolol-Ratiopharm 25 should occur gradually to avoid the development of withdrawal syndrome.